


1 **Triazolam**

2 トリアゾラム



3

4 $C_{17}H_{12}Cl_2N_4$: 343.21

5 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]

6 benzodiazepine

7 [28911-01-5]

8

9 Triazolam, when dried, contains not less than
10 98.0% and not more than 102.0% of triazolam
11 ($C_{17}H_{12}Cl_2N_4$).

12 **Description** Triazolam occurs as a white crystalline
13 powder.

14 It is sparingly soluble in *N,N*-dimethylformamide,
15 slightly soluble in ethanol (95), and practically insoluble in
16 water.

17 It shows crystal polymorphism.

18 **Identification** (1) Determine the absorption spectrum
19 of a solution of Triazolam in ethanol (95) (1 in 200,000) as
20 directed under Ultraviolet-visible Spectrophotometry
21 <2.24>, and compare the spectrum with the Reference Spec-
22 trum or the spectrum of a solution of Triazolam RS pre-
23 pared in the same manner as the sample solution: both spec-
24 tra exhibit similar intensities of absorption at the same
25 wavelengths.

26 (2) Determine the infrared absorption spectrum of Tri-
27 azolam, previously dried, as directed in the paste method
28 under Infrared Spectrophotometry <2.25>, and compare the
29 spectrum with the Reference Spectrum or the spectrum of
30 dried Triazolam RS: both spectra exhibit similar intensities
31 of absorption at the same wave numbers.

32 (3) Perform the test with Triazolam as directed under
33 Flame Coloration Test <1.04> (2): a green to green-blue
34 color appears.

35 **Melting point** <2.60> 239 – 243°C.

36 **Purity** (1) Chloride <1.03>— To 1.0 g of Triazolam add
37 50 mL of water, and allow to stand for 1 hour while occa-
38 sional shaking, and filter. Discard the first 10 mL of the
39 filtrate, pipet 25 mL of the subsequent filtrate, and add 6
40 mL of dilute nitric acid and water to make 50 mL. Perform
41 the test using this solution as the test solution. Prepare the

42 control solution with 0.40 mL of 0.01 mol/L hydrochloric
43 acid VS (not more than 0.028%).

44 (2) Heavy metals— Being specified separately when
45 the drug is granted approval based on the Law.

46 (3) Related substances— Dissolve 0.14 g of Triazolam
47 in 10 mL of *N,N*-dimethylformamide, and use this solution
48 as the sample solution. Pipet 1 mL of the sample solution,
49 add *N,N*-dimethylformamide to make exactly 100 mL, and
50 use this solution as the standard solution. Perform the test
51 with exactly 12 μ L each of the sample solution and stand-
52 ard solution as directed under Liquid Chromatography
53 <2.01> according to the following conditions. Determine
54 each peak area by the automatic integration method: the
55 area of peak other than triazolam obtained from the sample
56 solution is not larger than 1/5 times the peak area of tria-
57 zolam from the standard solution, and the total area of the
58 peaks other than triazolam is not larger than the peak area
59 of triazolam from the standard solution. For the areas of the
60 peaks, related substance A having the retention time of
61 about 0.7 to triazolam, related substance B having the re-
62 tention time of about 1.5, and related substance C having
63 the retention time of about 2.4, multiply their relative re-
64 sponse factors, 1.8, 0.6 and 4.3, respectively.

65 **Operating conditions**—

66 Detector, column, column temperature, mobile phase A,
67 mobile phase B, flowing of mobile phase, and flow rate:
68 Proceed as directed in the operating conditions in the Assay.

69 Time span of measurement: For 39 minutes after
70 injection, beginning after the solvent peak.

71 **System suitability**—

72 Test for required detectability: Pipet 1 mL of the stand-
73 ard solution, and add *N,N*-dimethylformamide to make ex-
74 actly 10 mL. Confirm that the peak area of triazolam ob-
75 tained with 12 μ L of this solution is equivalent to 7 to 13%
76 of that with 12 μ L of the standard solution.

77 System performance: When the procedure is run with 12
78 μ L of the standard solution under the above operating
79 conditions, the number of theoretical plates and the
80 symmetry factor of the peak of triazolam are not less than
81 4500 and not more than 1.6, respectively.

82 System repeatability: When the test is repeated 6 times
83 with 12 μ L of the standard solution under the above
84 operating conditions, the relative standard deviation of the
85 peak area of triazolam is not more than 2.0%.

86 **Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C,
87 4 hours).

88 **Residue on ignition** <2.44> Not more than 0.3% (1 g).

89 **Assay** Weigh accurately about 55 mg each of Triazolam
90 and Triazolam RS, previously dried, dissolve each in *N,N*-
91 dimethylformamide to make exactly 50 mL, and use these
92 solutions as the sample solution and the standard solution,

93 respectively. Perform the test with 12 μL each of the sam-
 94 ple solution and standard solution as directed under Liquid
 95 Chromatography <2.01> according to the following condi-
 96 tions, and determine the peak areas, A_T and A_S , of triazolam
 97 in each solution.

$$98 \quad \text{Amount (mg) of triazolam (C}_{17}\text{H}_{12}\text{Cl}_2\text{N}_4) \\ 99 \quad = M_S \times A_T / A_S$$

100 M_S : Amount (mg) of Triazolam RS taken

101 *Operating conditions* –

102 Detector: An ultraviolet absorption photometer
 103 (wavelength: 254 nm).

104 Column: A stainless steel column 4.6 mm in inside
 105 diameter and 25 cm in length, packed with phenylsilanized
 106 silica gel for liquid chromatography (5 μm in particle
 107 diameter).

108 Column temperature: A constant temperature of about
 109 40°C.

110 Mobile phase A: A mixture of methanol and diluted
 111 acetic acid-ammonium acetate buffer solution (pH 4.5) (1
 112 in 10) (14:11).

113 Mobile phase B: A mixture of methanol and diluted
 114 acetic acid-ammonium acetate buffer solution (pH 4.5) (1
 115 in 10) (19:1).

116 Flowing of mobile phase: Control the gradient by mixing
 117 the mobile phases A and B as directed in the following table.
 118

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 14	98	2
14 – 34	98 → 1	2 → 99
34 – 39	1	99

119
 120 Flow rate: 2.0 mL per minute.

121 *System suitability* –

122 System performance: When the procedure is run with 12
 123 μL of the standard solution under the above operating
 124 conditions, the number of theoretical plates and the
 125 symmetry factor of the peak of triazolam are not less than
 126 4500 and not more than 2.0, respectively.


127 System repeatability: When the test is repeated 6 times
 128 with 12 μL of the standard solution under the above
 129 operating conditions, the relative standard deviation of the
 130 peak area of triazolam is not more than 1.0%.

131 **Containers and storage** Containers – Tight containers.

132 **Others**

133 Related substance A:


134 3-Amino-6-chloro-4-(2-chlorophenyl)-2-methyl-3,4-dihy-
 135 droquinazolin-4-ol



136

137 Related substance B:


138 8-Chloro-6-(2-chlorophenyl)-1-ethenyl-4H-[1,2,4]tria-
 139 zolo[4,3-a][1,4]benzodiazepine



140

141 Related substance C:

142 8-Chloro-6-(2-chlorophenyl)-6-methoxy-1-methyl-
 143 4H,6H-[1,2,4]triazolo[4,3-a][1,4]benzoxazepine



144

145

146 **Add the following to 9.01 Reference**
 147 **Standards (1):**

148 **Triazolam RS**